Physician profile
Melisha Bissram
NPI 1942417183
$663.25
in general payments reported to CMS, 2019-2025
11 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $144 · 2022: $79.35 · 2023: $22.61 · 2024: $16.89 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184 · Education: $28.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.03 |
| Education | $28.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $290.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $113.88 | 2025 | |
| Mallinckrodt Hospital Products INC. | $37.14 | 2022-2023 | Acthar |
| Daiichi Sankyo INC. | $36.95 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $33.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.00 | 2019 | |
| Travere Therapeutics, INC. | $28.51 | 2024-2025 | Filspari |
| Mallinckrodt Enterprises LLC | $24.58 | 2019 | |
| Mannkind Corporation | $23.77 | 2025 | |
| Scpharmaceuticals INC. | $23.77 | 2025 | |
| Fresenius USA Marketing, INC. | $17.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melisha Bissram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.